CFDA official: Hand, foot and mouth disease vaccine has entered the final stage of review and will be launched soon

Source: Wang Lifeng, director of CFDA's Department of pharmacy and chemistry, July 4, 2014, introduced at this morning's press conference that EV71 inactivated (Vero cell) vaccine under research in China has successively completed clinical trials and entered the stage of production registration and evaluation, which is now in the final stage of evaluation and will soon be on the market "If you come out now, it will be the first EV71 vaccine in the world." Hand, foot and mouth disease (HFMD) is a kind of children's infectious disease, which mostly occurs in children under 5 years old It can cause herpes in hands, feet, mouth and other parts A few children can cause complications such as myocarditis, pulmonary edema, aseptic meningoencephalitis, etc if the disease develops rapidly, some severe children will die HFMD is often caused by enterovirus EV71 infection, and there is no corresponding vaccine at home and abroad HFMD vaccine belongs to one of the varieties with urgent domestic demand and great market potential At present, there are not a few enterprises involved in R & D The research and development leaders are domestic micro Valley biomedicine (belonging to Zhongsheng Co., Ltd.), Kexing Biology (NASDAQ: SVA) and Institute of medical biology of Chinese Academy of Medical Sciences (Kunming Institute), which have successively applied for the production approval of the vaccine; Kexing biology and Zhongsheng Co., Ltd even started to prepare supporting production workshops and GMP certification in the second half of last year In addition, Hualan Biology (002007 SZ) also declared the clinical application of the inactivated vaccine (Vero cell) for adsorbed HFMD (EV71 type) in February last year.